Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function

Details for Australian Patent Application No. 2012213963 (hide)

Owner GlycArt Biotechnology AG

Inventors Umana, Pablo; Bruenker, Peter; Ferrara, Claudia; Suter, Tobias

Agent Peter Maxwell & Associates

Pub. Number AU-A-2012213963

Parent 2010200408

Filing date 15 August 2012

Wipo publication date 6 September 2012

International Classifications

C12N 9/10 Enzymes, e.g. ligases (6.) - Transferases (2.)

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/30 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/32 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 9/24 Enzymes, e.g. ligases (6.) - acting on glycosyl compounds (3.2)

C12N 15/62 Mutation or genetic engineering - DNA sequences coding for fusion proteins

C12P 21/00 Preparation of peptides or proteins

A61K 38/00 Medicinal preparations containing peptides

Event Publications

30 August 2012 Complete Application Filed

6 September 2012 Application Open to Public Inspection

  Published as AU-A-2012213963

18 October 2012 Alteration of Name

  The name of the applicant has been altered to Roche GlycArt AG

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012213964-Methods of administering/dosing antiRSV antibodies for prophylaxis and treatment

2012213962-Ultra high affinity neutralizing antibodies